What's the function of HGH?

General name: Recombinant Human Growth Hormone for Injection
English Name: Recombinant Human Growth Hormone for Injection
Main ingredient: recombinant human growth hormone
Character: white lyophilized powder.
Pharmacokinetics
According to the literature, subcutaneous or intramuscular injection has the same effect. Subcutaneous injection usually brings higher serum GH concentration than intramuscular injection, but produces the same concentration of IGF-1. GH absorption is usually slow, plasma GH concentration usually peaks after 3-5 hours of administration, and the clearance half-life is generally 2-3 hours; GH is cleared through the liver and kidneys, and adults are faster than children, with very small amounts of unmetabolized GH directly removed from urine.
Indications: For the treatment of slow growth and severe burns in children with endogenous growth hormone deficiency, chronic renal failure and Turner's syndrome.
Usage and Dosage: Before use, add 1 ml of water for injection along the bottle wall slowly to lyophilized rhGH, shake slightly to make it all dissolved, do not shake violently.
The recommended dosage is 0.1-0.15IU/kg body weight/day, once a day, subcutaneously administered for 3 months to 3 years, or as directed by the doctor.
The recommended dose for the treatment of severe burns is 0.2-0.4 IU/kg body weight per day, once a day, subcutaneously injected for about 2 weeks.
Adverse reaction
Growth hormone can cause transient hyperglycemia, which usually returns to normal with prolonged use or withdrawal. About 1% of short stature children in clinical trials had side effects. The common local transient reactions (pain, anesthesia, redness, swelling, etc.) and fluid retention symptoms (peripheral edema, joint pain or myalgia) occurred earlier, but the incidence of these side effects decreased with the time of treatment, rarely affecting daily activities. Long-term injection of recombinant human growth hormone (rhGH) can cause antibody production in a small number of patients with low antibody binding and no definite clinical significance. However, if the expected growth effect is not achieved, there may be antibody production, antibody binding force more than 2 mg / L, may affect the efficacy.
taboo
1. Children with skeletal closure are prohibited.
2. Patients with tumor progression symptoms are prohibited.
3. Severe systemic infections and other critical patients are prohibited during acute shock period.
Matters needing attention
1, under the guidance of doctors for patients with clear diagnosis.
2, diabetics may need to adjust the dosage of antidiabetic drugs.
3. Patients with growth hormone deficiency caused by brain tumors or with a history of intracranial injury must be closely monitored for the progression or recurrence of their underlying diseases.
4. Simultaneous use of corticosteroids can inhibit the growth-promoting effect of growth hormone. Therefore, patients with ACTH deficiency should adjust the dosage of corticosteroids to avoid the inhibition of growth hormone.
5. A few patients may have hypothyroidism in the course of growth hormone therapy. They should be corrected in time to avoid affecting the therapeutic effect of growth hormone. This patient should be examined regularly for thyroid function and given thyroid hormone supplement if necessary.
6. Patients with endocrine disorders (including growth hormone deficiency) may be prone to femoral head epiphyseal plate spondylolisthesis. Lameness should be assessed during the treatment of growth hormone.
7. Sometimes growth hormone can lead to excessive insulin status, so it is necessary to pay attention to patients with impaired glucose tolerance.
8. Avoid overdosing. An overdose of growth hormone can lead to hypoglycemia, followed by hyperglycemia. Long-term overdosing may lead to acromegaly symptoms and signs and other reactions related to growth hormone overdosage.
9, the injection site should be constantly changed to prevent fat atrophy.
Medication for pregnant women and lactating women is unsuitable for use.
Drugs for Children: There is no significant difference in pharmacological toxicology and pharmacokinetics of growth hormone between children and adults. It can be safely used according to body weight.
Medication for elderly patients: There is no significant difference in pharmacological toxicology and pharmacokinetics of growth hormone between the elderly and adults, so it can be safely used.
Drug interaction
The use of glucocorticoids at the same time may inhibit the response of hormones, so the dosage of glucocorticoids in growth hormone therapy should not exceed the body surface area of 10-15 mg hydrocortisone per square meter, and the use of non-androgen steroids can further increase the growth rate.
Drug overdose
No case of acute overdose has been reported. However, overdoses can cause side effects, starting with hypoglycemia and then hyperglycemia, and prolonged overdoses can lead to symptoms and signs of acromegaly.